Adamis Pharmaceuticals Corporation (ADMP) Company Bio
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.
Adamis Pharmaceuticals Corporation (ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through its field sales force. As contemplated by the previously announced termination agreement between Adamis and Sandoz Inc., and the previously announced exclusive distribution and commercialization agreement between Adamis and USWM, USWM has been actively promoting SYMJEPI while preparing to launch through its field sales force.
Naloxone is an opioid antagonist used to treat narcotic overdoses. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. Rapid resuscitation of an opioid overdose with naloxone, an opioid antagonist, is critical as opioid induced toxicity results in rapid death, i.e., delaying adequate resuscitation can result in death.
Adamis Pharmaceuticals ([[ADMP]] +7.7%) inks an an agreement with Matrix Biomed for global rights to Tempol for the treatment of respiratory diseases, including COVID-19, in addition to a dermatology indication: preventing radiation dermatitis in patients undergoing treatment for cancer.Under the terms of the deal, Adamis paid Matrix $250K upfront plus...
Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of coronavirus and respiratory disease. Adamis Pharmaceuticals is … Full story available on Benzinga.com